With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
In an interview with Generics Bulletin, Julie Reed, executive director of the US Biosimilars Forum, says that the low uptake for Humira rivals in the US has “raised everyone’s attention to what is going on and what is wrong with the system.”
Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.
Despite increased pressures from inflation and dependence on international supply chains, the average cost of generics in Canada is 45% lower than in 11 comparator countries, the CGPA reports.
Following publication of the negotiating text of the proposed WHO Pandemic Agreement, the IGBA has expressed concern that “some issues have led to delays in reaching consensus and may threaten the viability of the negotiations,” while proposing solutions to perceived challenges and setbacks.
Generics Bulletin caught up with West Pharmaceutical Service’s David Maier, Vice President and General Manager of Global Generics at CPHI Barcelona to discuss sustainability in the industry.
Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.
A new voluntary certification from the AMR Industry Alliance and the British Standards Institution will assess pharmaceutical firms’ responsibility and sustainability when it comes to manufacturing antibiotic drugs, in an attempt to control the spread of antimicrobial resistance.
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.
As the antibiotics market recovers in the wake of the COVID-19 pandemic, Centrient CEO Rex Clements talks to Generics Bulletin about the firm’s recent sustainability milestones as well as the cost and policy challenges faced by European manufacturing.
Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.
Centrient has celebrated passing a “significant milestone in the clean production of antibiotics” after meeting Predicted No Effect Concentration discharge targets set by the AMR Industry Alliance across its entire oral antibiotics product range.
In an exclusive interview, the CEO of Olon unveils the strategy of the Italian Group to establish itself as a competitive and cost-effective API supplier to the generics industry, combined with offering sustainable, technologically advanced manufacturing services for biopharma innovators.
A commitment to supporting people has driven Zentiva through the challenges of COVID-19, and will continue to be a key feature in their strategy for continued growth moving forward.
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Teva has disclosed plans to focus on climate action and resilience, responsible use of natural resources and emissions, effluents and waste, as part of a long-term environmental sustainability commitment. Meanwhile, Hikma has at the same time committed “to further reducing our climate impact and improving the resilience of our business in the face of future climate change.”
Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.
In addition to securing supply for the short term amid the coronavirus pandemic, Apotex is also “actively preparing for longer term scenarios,” as Canada’s largest pharmaceutical manufacturer and API producer.